で公開中です! 詳しく見る
HAEのアイコン

Haemonetics

118.28 USD
-3.01
2.48%
終値時点 更新済み 10月16日 16:00 EDT
プレマーケット
時間外取引
118.52
+0.24
0.2%
1日
-2.48%
5日間
-0.35%
1か月
11.33%
3か月
50.68%
6か月
96.77%
年初来
47.89%
1年
137.65%
5年間
76.35%
10年間
243.14%
 

概要: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.

従業員数: 3,009

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 59.3%
ニュートラル 29.6%
ネガティブ 11.1%
ポジティブ
Zacks Investment Research
18 時間前
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
ネガティブ
Zacks Investment Research
昨日
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's MedSurg growth and NexSys PCS adoption support its prospects, but competitive pressures and unfavorable currency movements pose risks.
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
ポジティブ
Zacks Investment Research
3 日前
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
ポジティブ
Zacks Investment Research
7 日前
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
ポジティブ
Proactive Investors
8 日前
Haemonetics shares jump as CSL sets 2027 rollout of plasma devices
Haemonetics (NYSE:HAE) shares jumped over 13% to $115.20 on Thursday after CSL set out a timetable for moving its US plasma collection centers onto the company's devices. CSL Limited (ASX:CSL), the Australian biotechnology company, expects to finish rolling out Haemonetics' NexSys PCS devices with Persona PLUS technology and related disposables by the end of 2027.
Haemonetics shares jump as CSL sets 2027 rollout of plasma devices
ポジティブ
Barrons
8 日前
Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue
CSL Plasma plans to use Haemonetics' plasma collection equipment across all existing U.S. centers, expanding the scope of an earlier supply agreement.
Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue
ポジティブ
Zacks Investment Research
11 日前
PAHC vs. HAE: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
PAHC vs. HAE: Which Stock Is the Better Value Option?
ニュートラル
PRNewsWire
16 日前
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
BOSTON, Sept. 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, November 5, 2026.
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
ポジティブ
Zacks Investment Research
22 日前
Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?
ポジティブ
Zacks Investment Research
28 日前
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
価格チャートは Lightweight Charts™ を使用して実装されています